FILING ANALYSIS · MONDAY, NOVEMBER 2
CERUS CORP CERS — 8-K: Results of Operations and Financial Condition
neutral
Cerus Corporation reported a 10% year-over-year increase in product revenue to $57.7 million and announced positive topline results from the Phase 3 RedeS trial of the INTERCEPT Blood System for red blood cells, but operating expenses increased 5% year-over-year to $36.2 million
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →